The estimated Net Worth of Stephen Andrew Welch is at least $13.1 Thousand dollars as of 13 March 2023. Stephen Welch owns over 1,000 units of Mallinckrodt Plc stock worth over $13,105 and over the last 2 years Stephen sold MNK stock worth over $0.
Stephen has made over 1 trades of the Mallinckrodt Plc stock since 2023, according to the Form 4 filled with the SEC. Most recently Stephen bought 1,000 units of MNK stock worth $8,480 on 13 March 2023.
The largest trade Stephen's ever made was buying 1,000 units of Mallinckrodt Plc stock on 13 March 2023 worth over $8,480. On average, Stephen trades about 200 units every 0 days since 2022. As of 13 March 2023 Stephen still owns at least 38,545 units of Mallinckrodt Plc stock.
You can see the complete history of Stephen Welch stock trades at the bottom of the page.
Stephen's mailing address filed with the SEC is McDonnell Boulevard, Hazelwood, Saint Louis County, Missouri, 63042, United States.
Over the last 11 years, insiders at Mallinckrodt Plc have traded over $29,853,069 worth of Mallinckrodt Plc stock and bought 2,559,592 units worth $174,429,961 . The most active insiders traders include & Co. Inc. Paulson, James E Deerfield Mgmt L.P...., and Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of $10,061. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth $9,495.
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
Mallinckrodt Plc executives and other stock owners filed with the SEC include: